ClinicalTrials.gg
RecruitingNCT07236190NPC1-ADUpdated Oct 13, 2026

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

A Phase 2 interventional study of natural product combination-1 (NPC1) in Alzheimer Disease, Mild Cognitive Impairment (MCI) and Subjective Cognitive Decline (SCD), sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 13, 2026Eligibility revisedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 29 studies in Alzheimer Disease by Massachusetts General Hospital — 9 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Massachusetts General Hospital.

Planned enrollment
9th of 25
40 · median 20
Started
2026
with 3 others
Phase 2
3 of 29
1 open now
Registered
27th of 29
by date

Among the 29 studies in Alzheimer Disease by Massachusetts General Hospital, this one is the 9th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 2, and was the 27th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

9 of the 29 studies in Alzheimer Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Alzheimer Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology

03

Conditions studied

  • Alzheimer Disease
  • Mild Cognitive Impairment (MCI)
  • Subjective Cognitive Decline (SCD)

Keywords

  • Open Label
  • Dietary Supplements
  • Alzheimer's Disease
  • Mild Cognitive Impairment (MCI)
  • Intervention
  • early phase clinical trial
  • blood based biomarkers
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 55 and older, male and female;
  2. Subjective Cognitive Impairment or MCI or AD dementia per the Revised criteria for diagnosis and staging of Alzheimer's disease criteria;
  3. Clinical Dementia Rating \< or = to 2 and Mini Mental Status Exam > or = to 16;
  4. Modified Hachinski Ischemic Score \< or = to 4
  5. Geriatric Depression Scale - 15 \< 6 documenting absence from significant depressive syndromes
  6. Other medications including non-disease modifying for MCI and AD (e.g., acetylcholine esterase inhibitor, N-methyl D-aspartate receptor antagonist) stable > or = to 1-month prior to screening visit;
  7. Biomarker evidence of AD pathology: Plasma abeta42/40 ratio \< or = to 0.12 AND Plasma p-tau217 > or = to 2.1 pg/mL OR Amyloid PET positive (centiloid > or = to 20) as part of routine clinical care.
  8. Sufficient vision and hearing to complete all tests
  9. Study partner available with frequent (at least 1 hour/day or 1 day/week) contact with participant to provide collateral information about cognition, daily functioning, adverse events reporting, and support for study drug intake
  10. General health status that will not interfere with the ability to complete the prospective study (these conditions are listed below in the study exclusion list)

Exclusion criteria

Exclusion Criteria:

  1. CDR > 2 \< 16;
  2. Other significant CNS disease within the last 2 years (i.e., brain tumor, seizure disorder, subdural hematoma, cranial arteritis, cortical stroke) That would impact the participant's ability to complete the study;
  3. Alcohol or substance abuse according to criteria within the last 2 years
  4. Major depressive disorder or anxiety within the last year; Schizophrenia, bipolar disorder or other major psychiatric disorder defined by DSM-IV criteria
  5. Abnormal labs indicating potential reversible causes of dementing illness such as vitamin B12 deficiency, thyroid disease, or UTI (documented bacterial colonization is acceptable) or > 1.2 (1.3 or higher) or \< 100 K/uL at screening
  6. Unstable or significantly symptomatic CVD (e.g. CAD with frequent angina, CHF with dyspnea at rest)
  7. Hypertension: defined as uncontrolled BP > 160/100
  8. Clinical symptomatic orthostatic hypotension
  9. Diabetes mellitus that requires insulin injections
  10. Hachinski ischemic score > or = to 4
  11. Cancer within the last 5 years, apart from localized prostate cancer (Gleason Grade \< 3) and non- skin cancers (melanoma).
  12. Illness that requires >1 visit /month to a clinician
  13. Medications and dietary supplements:

    • a. AD disease modifying monoclonal antibody treatment e.g., donanemab (Kisunla) or lecanemab (Leqembi). Wash out period of five half-lives prior to screening visit is permitted e.g., > or = 60 days since last dose of donanemab and > or = 35 days since last dose of lecanemab)
    • b. Dietary supplements containing parthenolide or ipriflavone (1-month wash out period prior to screening is permitted)
    • c. CNS active meds that have not been on stable doses for at least 1 month prior to screening visit e.g., cimetidine, beta-blockers, and SSRIs
    • d. Neuroleptics, antiparkinsonian agents, systemic , and narcotic analgesics; in the case where these were used for a self-limited time they must have been discontinued for a period of five half-lives prior to screening visit
    • e. Over the counter supplements are not by themselves exclusionary, however, participants are asked not to change the dosing regimen over the course of the trial unless medically indicated; the presence and dose of these product are recorded
    • f. Anticoagulation therapy: Vitamin K antagonist: warfarin (Coumadin, jantoven)
  14. Participation in any Alzheimer's Disease interventional trial. Participation in other non-AD related trials will be evaluated at the discretion of the investigator
  15. Currently pregnant. Positive pregnancy tests during the course of the trial will be evaluated at the discretion of the investigator.

Women of Child Bearing Potential ()

For the purposes of this study, women of childbearing potential are defined as all women who are capable of becoming pregnant, unless they meet one of the following criteria:

  1. 12-months
  2. Post-hysterectomy/surgically sterile

If a female Participant does not meet either of these criteria they will be considered of childbearing potential and will have a serum pregnancy test performed at Screening, Visit 3 (2 months), Visit 6 (5 months), and Visit 10 (8 months).

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Lead-in observational period

    Serial blood-based biomarker collection

  • Active comparator
    Active interventional period

    Serial post treatment blood-based biomarkers

    Combination Product: natural product combination-1 (NPC1)

Interventions

  • Combination productnatural product combination-1 (NPC1)

    parthenolide plus ipriflavone

    Also known as: parthenolide, ipriflavone

06

What researchers measure

Primary outcomes

  1. plasma p-tau217

    Intra-individual changes from pre-treatment observational period to post-treatment interventional period

    Time frame: 6 months

  2. plasma glial fibrillary acidic protein

    Intraindividual changes

    Time frame: 6 months

  3. plasma neurofilament light chain

    Intra-individual changes

    Time frame: 6 months

  4. plasma abeta42 / abeta40

    Intraindividual changes

    Time frame: 6 months

  5. Safety and Tolerability of NPC1

    Assessment of Adverse Events Related to NPC1 Treatment

    Time frame: Baseline through 6 months

Secondary outcomes

  1. plasma hsTNFalpha

    intra-individual changes

    Time frame: 6 months

Other outcomes

  1. Safety and Tolerability

    Analysis of Complete Blood Count (CBC) with differential values from baseline through the end of the 6 month treatment period will be measured to assess for safety and tolerability of NPC1 intervention.

    Time frame: Baseline through 6 months

  2. Safety and Tolerability

    Analysis of Comprehensive Metabolic Panel (CMP) values from baseline through the end of the 6 month treatment period will be measured to assess for safety and tolerability of NPC1 intervention.

    Time frame: Baseline through 6 months

  3. Safety and Tolerability

    Analysis of Prothrombin time/International Normalized Ratio (PT/INR) values from baseline through the end of the 6 month treatment period will be measured to assess for safety and tolerability of NPC1 intervention.

    Time frame: Baseline through 6 months

  4. Clinical Dementia Rating sum of boxes

    Time frame: 6 months

  5. Montreal Cognitive Assessment

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Dodge HH, Chen L, Wu CY, Cutter G, Bowman GL, Feldman HH, Arnold SE. Seeking optimal repeated fluid biomarker assessments to enhance precision and statistical power in clinical trials: SLIM method. Alzheimers Dement. 2025 Oct;21(10):e70787. doi: 10.1002/alz.70787. PubMed 41122812 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 14 months is below that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2025
First posted
Nov 19, 2025
StartActual
Apr 1, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 inclusion criteria edited; 6 exclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedSubjective Cognitive Impairment or MCI or AD dementia per NIA-AA 2011the Revised criteria for diagnosis and staging of Alzheimer's disease criteria;
  • EditedOther medications including non-disease modifying for MCI and AD (e.g., acetylcholine esterase inhibitor, N-methyl D-aspartate receptor antagonist) stable > or = to 31-months month prior to screening visit;
  • EditedBiomarker evidence of AD pathology: Plasma abeta42/40 ratio < or = to 0.12 AND Plasma p-tau217 > or = to 02.251 pg/mL OR Amyloid PET positive (centiloid > or = to 20) as part of routine clinical care.
Exclusion criteria
  • EditedSignificantOther significant CNS disease within the last 2 years (i.e., brain tumor, seizure disorder, subdural hematoma, cranial arteritis, cortical stroke) That would impact the participant's ability to complete the study;
  • EditedAbnormal labs indicating potential reversible causes of dementing illness such as vitamin B12 deficiency, thyroid disease, or UTI (documented bacterial colonization is acceptable) or INR > 1.2 (1.3 or higher) or platelets < 100 K/uL at screening
  • ChangedBefore a. AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemabNow a. AD disease modifying monoclonal antibody treatment e.g., donanemab (Kisunla) or lecanemab (Leqembi). Wash out period of five half-lives prior to screening visit is permitted e.g., > or = 60 days since last dose of donanemab and > or = 35 days since last dose of lecanemab)
  • Editedb. Dietary supplements containing parthenolide or ipriflavone (1-month wash out period prior to enrollmentscreening is permitted)
  • Editedc. CNS active meds that have not been on stable doses for at least 2 months1 month prior to screening visit e.g., cimetidine, beta-blockers, and SSRIs
  • Editedd. Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounteddiscontinued for a period of five half-lives prior to baselinescreening visit
  • Addedf. Anticoagulation therapy: Vitamin K antagonist: warfarin (Coumadin, jantoven)
Oct 13, 2026
Contact
Study contact changed: g•••@mgh.harvard.edu · •••5197→n•••@mgb.org · •••1520; b•••@mgh.harvard.edu · •••1520→n•••@mgb.org · •••3918. See the current contact
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Massachusetts General Hospital · Boston, United StatesContact g•••@mgh.harvard.edu · •••5197→n•••@mgb.org · •••1520
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Eligibility 3 inclusion criteria edited; 6 exclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedSubjective Cognitive Impairment or MCI or AD dementia per NIA-AA 2011the Revised criteria for diagnosis and staging of Alzheimer's disease criteria;
    • EditedOther medications including non-disease modifying for MCI and AD (e.g., acetylcholine esterase inhibitor, N-methyl D-aspartate receptor antagonist) stable > or = to 31-months month prior to screening visit;
    • EditedBiomarker evidence of AD pathology: Plasma abeta42/40 ratio < or = to 0.12 AND Plasma p-tau217 > or = to 02.251 pg/mL OR Amyloid PET positive (centiloid > or = to 20) as part of routine clinical care.
    Exclusion criteria
    • EditedSignificantOther significant CNS disease within the last 2 years (i.e., brain tumor, seizure disorder, subdural hematoma, cranial arteritis, cortical stroke) That would impact the participant's ability to complete the study;
    • EditedAbnormal labs indicating potential reversible causes of dementing illness such as vitamin B12 deficiency, thyroid disease, or UTI (documented bacterial colonization is acceptable) or INR > 1.2 (1.3 or higher) or platelets < 100 K/uL at screening
    • ChangedBefore a. AD disease modifying monoclonal antibody treatment e.g., aducanumab or lecanemabNow a. AD disease modifying monoclonal antibody treatment e.g., donanemab (Kisunla) or lecanemab (Leqembi). Wash out period of five half-lives prior to screening visit is permitted e.g., > or = 60 days since last dose of donanemab and > or = 35 days since last dose of lecanemab)
    • Editedb. Dietary supplements containing parthenolide or ipriflavone (1-month wash out period prior to enrollmentscreening is permitted)
    • Editedc. CNS active meds that have not been on stable doses for at least 2 months1 month prior to screening visit e.g., cimetidine, beta-blockers, and SSRIs
    • Editedd. Neuroleptics, antiparkinsonian agents, systemic corticosteroids, and narcotic analgesics; in the case where these were used for a self-limited time they must have been discounteddiscontinued for a period of five half-lives prior to baselinescreening visit
    • Addedf. Anticoagulation therapy: Vitamin K antagonist: warfarin (Coumadin, jantoven)
    Contact Study contact changed: g•••@mgh.harvard.edu · •••5197→n•••@mgb.org · •••1520; b•••@mgh.harvard.edu · •••1520→n•••@mgb.org · •••3918. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Massachusetts General Hospital · Boston, United StatesContact g•••@mgh.harvard.edu · •••5197→n•••@mgb.org · •••1520
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07236190
Responsible party
Gene L. Bowman, ND, MPH (Director of Clinical Trials, Massachusetts General Hospital) — Principal investigator
First posted
Nov 19, 2025
Start date
Apr 1, 2026
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Brianna Wang, MS
Contact
npc1clinicaltrial@mgb.org
857-282-1520
Ashley Sanchez Bermeo
Contact
npc1clinicaltrial@mgb.org
857-282-3918
Gene Bowman, ND, MPH
principal investigator · Harvard/Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion